Wearables Fundraising: Active VCs & Consumer-Health

How to raise venture capital for a wearables, smart-ring, CGM, or consumer-health hardware startup in 2026.

How to Raise Venture Capital for a Wearables Startup

Wearables — Apple Watch, Fitbit (Google), Garmin, Whoop, Oura, Ultrahuman, RingConn, Circular, Amazfit / Zepp, Withings, Polar, plus CGM-consumer (Levels, Nutrisense, Signos, Lingo by Abbott, Stelo by Dexcom), medical-grade (Empatica, BioIntelliSense, iRhythm), and emerging categories (Humane pin cautionary tale, Rabbit R1, Bee AI, Friend, Limitless) — spans fitness / wellness, health monitoring, and AI-native wearables.

Why wearables is a distinct fundraising category

Wearables investors underwrite hardware BOM + margin (typical 40–55% gross margin at scale, negative early), subscription attach rate (Whoop 100%, Oura ~85% on Gen 4, Ultrahuman variable — critical for LTV), FDA regulatory pathway for health claims (510(k) for AFib, De Novo for novel biomarkers, wellness for fitness), retail vs D2C distribution economics (Apple / Amazon / Best Buy / Target take 30–50%), Section 301 China tariffs, and the graveyard of hardware startups (Humane pin, Jawbone, Pebble, Fitbit's decline pre-Google) that reset expectations for consumer hardware at venture.

The most active wearables VCs

Consumer / hardware focused: True Ventures, Foundry Group, Lerer Hippeau, Forerunner Ventures, Maveron, Bolt, Root Ventures, Trucks Venture Capital, Autotech Ventures, plus Bond Capital, GV, Founders Fund, a16z Bio + Health, Khosla, Kleiner, Bessemer, and Insight.

Multi-stage generalists active in wearables: Sequoia, a16z, Coatue, Tiger, Lightspeed, General Catalyst, Accel, and Index.

Strategic capital: Google Ventures (post-Fitbit), Samsung NEXT, Qualcomm Ventures (Snapdragon Wear + W5), Verily (Alphabet), Fitbit / Google Health, Withings (via Nokia), Garmin (limited CVC), plus health strategics Optum Ventures, CVS Health Ventures, Humana Studio H, and Dexcom / Abbott / Medtronic corporate development for CGM-adjacent.

FDA pathways for health claims

Wellness claims (fitness, sleep, stress, activity) require no FDA clearance — most consumer wearables (Whoop, Oura, Fitbit fitness features) stay wellness. Aggressive health claims trigger FDA scrutiny.

510(k) clearance is standard for AFib detection (Apple Watch, Fitbit, Withings ScanWatch), ECG (Apple Watch, KardiaMobile), SpO2 as medical device (varies). $50K–$500K, 6–12 months.

De Novo for novel biomarkers (continuous glucose consumer use, novel HRV-based diagnostics). $500K–$2M, 12–24 months. Dexcom Stelo + Abbott Lingo cleared as OTC CGMs in 2024 — category-defining.

PMA (Class III) rare for consumer wearables. Class II general controls apply to most cleared health features.

Hardware unit economics

Consumer wearables target 40–55% gross margin at scale (BOM $30–$150, retail $199–$499). Section 301 China tariffs (25% on Chinese-assembled electronics, expanded 2024–2025) and USMCA sourcing rules materially affect margin. Retail (Apple Store, Amazon, Best Buy, Target, Costco) takes 30–50%; D2C keeps margin but requires CAC. Subscription attach rate is critical — Whoop's model (0 hardware cost + $30/mo) locks LTV; Oura's $299 hardware + $6/mo optional membership is a hybrid; pure hardware (Apple Watch, Garmin) relies on device replacement cycle (2–4 years).

Subscription attach as the venture unlock

Pure hardware startups struggle at venture — Fitbit's decline pre-Google acquisition, Jawbone's bankruptcy, Pebble's fire-sale, Humane pin's write-down are reference cases. Subscription attach transforms unit economics: Whoop (100% subscription, hardware given free) reaches $500+ LTV; Oura (85% subscription attach on Gen 4) reaches $400+ LTV; Ultrahuman (variable) is on the venture threshold. Investors underwrite subscription attach rate and 24-month retention as the primary Series B milestone.

Common mistakes when raising for wearables

Pure hardware business model without subscription attach. Naming 'retail partnerships' without signed placement. Ignoring Section 301 China tariff impact on margin. Overpromising FDA clearance on wellness devices. Underestimating retail take rates (30–50%). Modeling first-year LTV without device replacement cycle honesty. Not addressing the wearables graveyard (Humane, Jawbone, Pebble, Fitbit's decline) in the diligence narrative.

Frequently asked questions

Which are the most active wearables VCs in 2026?
True Ventures, Foundry Group, Lerer Hippeau, Forerunner Ventures, Maveron, Bolt, Root Ventures, plus Bond Capital, GV, Founders Fund, Andreessen Horowitz Bio + Health, Khosla, Kleiner, Bessemer, and Insight lead the dedicated set. Generalists Sequoia, a16z, Coatue, Tiger, Lightspeed, General Catalyst, Accel, and Index are active. Strategic capital from Google Ventures (post-Fitbit), Samsung NEXT, Qualcomm Ventures (Snapdragon Wear + W5), Verily, Withings, Optum Ventures, CVS Health Ventures, Humana Studio H, plus Dexcom, Abbott, and Medtronic corporate development for CGM-adjacent.
Do wearables need FDA clearance?
Only for medical claims. Wellness features (fitness, sleep, stress, activity) require no FDA clearance and most consumer wearables stay wellness. 510(k) clearance is standard for AFib detection (Apple Watch, Fitbit, Withings ScanWatch) and ECG (Apple Watch, KardiaMobile) at $50K–$500K and 6–12 months. De Novo for novel biomarkers like consumer CGM at $500K–$2M and 12–24 months — Dexcom Stelo and Abbott Lingo received OTC CGM clearance in 2024, a category-defining precedent.
Why is subscription attach the venture unlock?
Pure hardware wearables struggle at venture — Fitbit's decline pre-Google acquisition, Jawbone's bankruptcy, Pebble's fire-sale, and Humane pin's write-down are reference cases. Subscription attach transforms unit economics: Whoop (100% attach, hardware given free) reaches $500+ LTV; Oura (85% attach on Gen 4) reaches $400+ LTV. Investors underwrite subscription attach rate and 24-month retention as the primary Series B milestone.
What are realistic hardware unit economics for wearables?
Target 40–55% gross margin at scale. BOM runs $30–$150, retail $199–$499. Section 301 China tariffs (25% on Chinese-assembled electronics, expanded 2024–2025) and USMCA sourcing rules affect margin materially. Retail channels (Apple Store, Amazon, Best Buy, Target, Costco) take 30–50%; D2C keeps margin but requires CAC. Device replacement cycle runs 2–4 years for pure hardware.
How do investors underwrite the wearables graveyard?
Humane pin's write-down, Jawbone's bankruptcy, Pebble's fire-sale, and Fitbit's decline pre-Google acquisition are diligence reference cases. Companies must show why their thesis is de-risked — subscription attach rate, FDA moat, exclusive distribution, or a category-defining biomarker (like OTC CGM). Pure hardware without subscription attach is not a diligence-passing narrative in 2026.

Related fundraising verticals (40)

Investor directory · Fundraising library · Articles A–Z · Company funding database